Subscribe
Photo Nature Travel / Shutterstock.com
14 January 2025NewsBig PharmaLiz Hockley

Novartis wins appeal in MSN clash over heart drug generic

Federal circuit reverses district court’s ruling to revive combination patent | Novartis says patent has paediatric exclusivity expiring in July 2025.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
MSN scores win in battle with Novartis over heart drug generic
22 October 2024   Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
Big Pharma
Novartis fails to block first heart-failure generic by Indian rival
13 August 2024   Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Americas
MSN scores win in battle with Novartis over heart drug generic
22 October 2024   Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
Big Pharma
Novartis fails to block first heart-failure generic by Indian rival
13 August 2024   Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More on this story

Americas
MSN scores win in battle with Novartis over heart drug generic
22 October 2024   Columbia court backs FDA approval of Entresto generic I Novartis appealing August ruling in Delaware that denied injunction.
Big Pharma
Novartis fails to block first heart-failure generic by Indian rival
13 August 2024   Delaware judge denies pharma giant’s request for injunction on rivals’ generic of Entresto | Novartis ‘unlikely to succeed’ in proving infringement | Lawsuit is one of several attempts to preserve exclusivity of the drug ahead of patent expiry and US price caps.
Generics
Novartis vows to challenge heart drug patent loss
11 July 2023   Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More features

GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
The rise of pro-NPE and patent sentiment in the US